In Massachusetts, TEPHA Inc. completed a buy-out of its royalty obligation to Metabolix, Inc., its former licensor and parent company. TEPHA develops implantable medical devices based on biomaterials, including a biologic polymer called poly4hydroxybutyrate (P4HB) which is made through a fermentation process. Andrew Joiner, President and CEO of Tepha, told PR Newsire “The buy-out of our royalty obligation in conjunction with Metabolix was financially advantageous for both companies. Specifically for Tepha, the cash flow from our savings will help finance the continued development of our core technology as well as pre-clinical and clinical testing of new applications.” TEPHA plans on using its P4HB-based fibers to expand into collagen, antibiotic coatings and non-woven materials in new markets.
Latest article
Starbucks disappointed in Cali compostable cup trial
In California, Starbucks is winding down a compostable cups trial following disappointing results. The fiber-based cups, which the coffee giant began trialing in West...
Funding shortfall forces NovoNutrients to launch asset sale
In California, gas fermentation firm NovoNutrients has ceased operations and is looking for a buyer for its assets, citing difficulty securing sufficient funding.
The...
Mara Renewables secures $9.1M to boost Omega-3 DHA
In Canada, Mara Renewables has received US$9.1 million from S2G Investments to expand R&D and capacity for its algae-based omega‑3 DHA platform.
The vital...